Skip to main content

Remote Job Finders (RJF)

US explores China biotech restrictions, exempts licensing deals

A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security drew cautious statements from across the industry, with leaders vowing to ensure innovation isn’t stifled.

AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations

AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.

Opinion: Your company isn’t paying you what you’re worth

Compensation can feel like a verdict on your value. Executive coach Angela Justice explains why companies are usually pricing the job, not the person doing it—and how understanding the difference can help you make better career decisions.

EyePoint will halve workforce, end pivotal wet AMD trials early following second fail

EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shifting attention to the asset’s potential in diabetic macular edema.

China tightens grip on biotech platform ownership but foreign licensing deals still okay

The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements.
Scroll to top